Both in Pharmaceuticals
Keros Therapeutics vs Cartesian Therapeutics
Over the past year KROS returned −22.9% and RNAC returned −30.4%; their daily moves had a correlation of 0.36.
KROS −22.9% RNAC −30.4%Growth of $1, one year, split-adjusted
| Metric | KROS | RNAC |
|---|---|---|
| Price | $10.66 | $6.27 |
| Market cap | $211.4M | $189.7M |
| Today | −3.96% | −4.71% |
| 1 month | −6.2% | −20.2% |
| 6 months | −8.7% | −10.9% |
| Year to date | −47.6% | −13.0% |
| 1 year | −26.4% | −35.0% |
| Revenue growth (YoY) | −100.0% | −100.0% |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 14.1× | 128.4× |
| Net cash | $257.6M | $94.8M |
| Dividend yield | — | — |
| Volatility (60d) | 45.5% | 48.5% |
| Short % of float | 6.2% | 15.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).